HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Mario Campone Selected Research

NVP-BKM120

1/2020Buparlisib plus carboplatin or lomustine in patients with recurrent glioblastoma: a phase Ib/II, open-label, multicentre, randomised study.
7/2019Benefits versus risk profile of buparlisib for the treatment of breast cancer.
11/2018Buparlisib plus fulvestrant versus placebo plus fulvestrant for postmenopausal, hormone receptor-positive, human epidermal growth factor receptor 2-negative, advanced breast cancer: Overall survival results from BELLE-2.
12/2017Efficacy of buparlisib in treating breast cancer.
11/2017PIKHER2: A phase IB study evaluating buparlisib in combination with lapatinib in trastuzumab-resistant HER2-positive advanced breast cancer.
1/2017Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Mario Campone Research Topics

Disease

160Breast Neoplasms (Breast Cancer)
11/2022 - 03/2002
89Neoplasms (Cancer)
01/2022 - 07/2003
18Triple Negative Breast Neoplasms
05/2022 - 11/2013
13Neutropenia
10/2021 - 12/2006
12Neoplasm Metastasis (Metastasis)
01/2021 - 08/2009
10Diarrhea
01/2021 - 11/2011
9Nausea
01/2021 - 12/2006
8Disease Progression
01/2022 - 11/2007
8Vomiting
01/2021 - 12/2006
8Glioblastoma (Glioblastoma Multiforme)
12/2020 - 03/2009
7Fatigue
01/2021 - 11/2007
7Carcinoma (Carcinomatosis)
12/2020 - 10/2015
6Brain Neoplasms (Brain Tumor)
01/2020 - 03/2009
6Carcinogenesis
11/2013 - 07/2003
5Glioma (Gliomas)
01/2022 - 06/2012
5Exanthema (Rash)
10/2021 - 01/2017
5Hyperglycemia
01/2019 - 11/2011
5Asthenia
12/2018 - 11/2011
4Prostatic Neoplasms (Prostate Cancer)
10/2020 - 03/2010
4Stomatitis
11/2017 - 12/2006
3Pain (Aches)
01/2021 - 06/2018
3Endometrial Neoplasms (Endometrial Cancer)
10/2020 - 01/2018
3Adenocarcinoma
05/2020 - 01/2006
3Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung)
01/2020 - 03/2008
3Febrile Neutropenia
01/2018 - 12/2006
3Leukopenia
11/2017 - 12/2014
3Inflammatory Breast Neoplasms
04/2016 - 04/2012
3Pneumonia (Pneumonitis)
10/2013 - 02/2012

Drug/Important Bio-Agent (IBA)

42Hormones (Hormone)IBA
11/2022 - 09/2005
31Trastuzumab (Herceptin)FDA Link
10/2021 - 07/2003
25ErbB Receptors (EGF Receptor)IBA
11/2022 - 12/2006
18EverolimusFDA Link
11/2022 - 06/2009
18Docetaxel (Taxotere)FDA Link
11/2019 - 09/2005
17Biomarkers (Surrogate Marker)IBA
12/2021 - 03/2006
17Proteins (Proteins, Gene)FDA Link
01/2019 - 03/2006
15Aromatase InhibitorsIBA
11/2022 - 02/2012
14human ERBB2 proteinIBA
10/2022 - 12/2009
14Estrogen ReceptorsIBA
01/2022 - 04/2006
14AnthracyclinesIBA
09/2021 - 12/2006
12exemestane (Aromasin)FDA Link
12/2020 - 02/2012
12Progesterone Receptors (Progesterone Receptor)IBA
10/2020 - 04/2006
11TOR Serine-Threonine KinasesIBA
11/2022 - 12/2010
11Fulvestrant (Faslodex)FDA Link
01/2022 - 01/2017
10ribociclibIBA
10/2022 - 11/2016
10Letrozole (Femara)FDA LinkGeneric
10/2022 - 06/2009
10Capecitabine (Xeloda)FDA Link
12/2019 - 12/2006
9Phenobarbital (Luminal)FDA Link
12/2021 - 11/2014
9Pharmaceutical PreparationsIBA
12/2021 - 11/2011
9DNA (Deoxyribonucleic Acid)IBA
01/2020 - 09/2005
9taxaneIBA
11/2019 - 12/2006
9Epirubicin (Ellence)FDA LinkGeneric
11/2019 - 12/2004
9Cyclophosphamide (Cytoxan)FDA LinkGeneric
11/2019 - 03/2006
8Epidermal Growth Factor (EGF)IBA
10/2021 - 07/2007
8Paclitaxel (Taxol)FDA LinkGeneric
10/2020 - 03/2002
7Carboplatin (JM8)FDA LinkGeneric
01/2022 - 07/2007
6Biological ProductsIBA
10/2021 - 09/2005
6NVP-BKM120IBA
01/2020 - 01/2017
6Temozolomide (Temodar)FDA LinkGeneric
01/2020 - 03/2009
6Fluorouracil (Carac)FDA LinkGeneric
11/2019 - 03/2006
6Bevacizumab (Avastin)FDA Link
11/2019 - 04/2012
6ixabepilone (BMS 247550)FDA Link
11/2018 - 11/2007
5Fluorodeoxyglucose F18 (Fludeoxyglucose F 18)FDA Link
12/2021 - 12/2006
5Alanine Transaminase (SGPT)IBA
10/2021 - 01/2017
5Taxoids (Taxanes)IBA
09/2021 - 07/2003
5abemaciclibIBA
04/2021 - 11/2017
5pertuzumabIBA
01/2020 - 05/2013
5Phosphatidylinositol 3-Kinase (1 Phosphatidylinositol 3 Kinase)IBA
01/2020 - 01/2017
5Lapatinib (GW572016)FDA Link
11/2017 - 12/2006
4Aspartate Aminotransferases (Aspartate Transaminase)IBA
10/2021 - 01/2017
4AlpelisibIBA
02/2021 - 01/2019
4Poly(ADP-ribose) Polymerase InhibitorsIBA
10/2020 - 08/2014
4Lomustine (CCNU)FDA Link
01/2020 - 09/2013
4Vinorelbine (Navelbine)FDA LinkGeneric
12/2019 - 04/2009
4Ado-Trastuzumab EmtansineIBA
01/2019 - 04/2015
4Tyrosine Kinase InhibitorsIBA
01/2017 - 12/2006
4vinflunineIBA
09/2016 - 10/2005
3Monoclonal AntibodiesIBA
01/2022 - 01/2006
3GemcitabineFDA Link
01/2022 - 10/2006
3AntibodiesIBA
07/2021 - 05/2020
3PlatinumIBA
10/2020 - 09/2007
3AntigensIBA
05/2020 - 01/2011
3CytokinesIBA
01/2020 - 09/2009
3Androgen Receptors (Androgen Receptor)IBA
12/2019 - 01/2015
3eribulinFDA Link
12/2019 - 09/2010
3Phosphatidylinositols (Phosphatidylinositol)IBA
07/2019 - 09/2016
3Cyclin-Dependent Kinases (cdk Proteins)IBA
02/2019 - 11/2016
3ParaffinIBA
01/2019 - 11/2014
3Formaldehyde (Formol)FDA Link
01/2019 - 11/2014
3palbociclibIBA
10/2018 - 04/2018
3Type 1 Fibroblast Growth Factor Receptor (Fibroblast Growth Factor Receptor 1)IBA
10/2017 - 07/2013
3Doxorubicin (Adriamycin)FDA LinkGeneric
01/2017 - 01/2013

Therapy/Procedure

58Therapeutics
11/2022 - 10/2003
47Drug Therapy (Chemotherapy)
05/2022 - 11/2004
13Neoadjuvant Therapy
05/2022 - 12/2006
8Radiotherapy
01/2022 - 12/2009
8Adjuvant Chemotherapy
01/2019 - 12/2006
6Aftercare (After-Treatment)
03/2021 - 12/2006
3Immunotherapy
12/2020 - 01/2011
3Mastectomy (Mammectomy)
01/2020 - 07/2007
2Chemoradiotherapy
01/2022 - 10/2016